COVID-19 after rituximab therapy in cSLE patients
Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Therapeutic Advances in Vaccines and Immunotherapy |
Online Access: | https://doi.org/10.1177/25151355231181242 |